yes
as we now on the cusp of entering phase 11
i see this replicating the path of neu
except with multiple times potential revenue prospects, as a result of much deeper need in patient population with added on wider applications across medical needs
latest broker reports for neu anticipate fair value price target of around $10
with similar amount of shares on issue i cant see why recce couldnt indeed exceed such value expectations
given other similar precedents seen recently on little researched emerging biotechs a forecast valuation along those lines could clearly emerge
neu with limited applications was priced around a dollar a year or so ago now what 5.78 with targets of $10
recce seems a really good investment to me at this sub 1$ level with little downside
if as expected now phase 1 tox human trials wrap up by end august and phase 11 schedules announced accordingly
i think we will start to see a substantial gathering of interest and subsequent rerating
have a peek at nsu
just say later i told ya so !
thanks for reading
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
yesas we now on the cusp of entering phase 11 i see this...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
(20min delay)
|
|||||
Last
51.0¢ |
Change
-0.015(2.86%) |
Mkt cap ! $118.1M |
Open | High | Low | Value | Volume |
52.0¢ | 52.0¢ | 50.5¢ | $40.89K | 79.63K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 677 | 51.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
52.5¢ | 392 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 677 | 0.510 |
2 | 3947 | 0.505 |
2 | 29692 | 0.500 |
1 | 12500 | 0.495 |
3 | 86124 | 0.490 |
Price($) | Vol. | No. |
---|---|---|
0.525 | 392 | 1 |
0.530 | 10000 | 1 |
0.540 | 10341 | 1 |
0.545 | 1834 | 1 |
0.550 | 59490 | 3 |
Last trade - 15.59pm 13/09/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online